Quick Answer
Palomino Laboratories Inc. reported Net Income of -$3.16 million for fiscal year 2025.
Palomino Laboratories Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$3.16M -19428.3% |
-$16.2K +80.7% |
-$83.9K | — |
| Diluted EPS | -$0.47 -4181.8% |
-$0.01 +35.3% |
-$0.02 | — |
| Total Assets | $8.43M +6006.2% |
$138.1K +36248.7% |
$380.00 -24.0% |
$500.00 |
| Cash and Equivalents | $8.12M +5931.2% |
$134.7K +35336.1% |
$380.00 -24.0% |
$500.00 |
| Stockholders Equity | $8.10M +44335.2% |
-$18.3K -768.4% |
-$2.1K +92.4% |
-$27.8K |
| Operating Income | -$2.70M -44042.3% |
-$6.1K +92.7% |
-$83.9K | — |
| Shares Outstanding | 18.77M +317.1% |
4.50M -10.0% |
5.00M +0.0% |
5.00M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.82M | -28710.2% | -568.6% |
| Diluted EPS | September 30, 2025 | -$0.54 | — | -5900.0% |
| Total Assets | September 30, 2025 | $8.31M | +2581502.8% | +440427.9% |
| Cash and Equivalents | September 30, 2025 | $7.90M | — | +5764.2% |
| Stockholders Equity | September 30, 2025 | $7.31M | +87763.3% | +1735.3% |
| Operating Income | September 30, 2025 | -$1.60M | -129958.5% | -4414.8% |
| Shares Outstanding | September 30, 2025 | 17.61M | +252.2% | +252.2% |
- Palomino Laboratories Inc. reported Net Income of -$3.16 million for fiscal year 2025.
- Palomino Laboratories Inc. showed a decrease of -19428.3% in Net Income compared to the prior fiscal year.
- Palomino Laboratories Inc. reported Diluted EPS of $0.47 per share (loss) for fiscal year 2025.
- Palomino Laboratories Inc. showed a decrease of -4181.8% in Diluted EPS compared to the prior fiscal year.
- Palomino Laboratories Inc. reported Total Assets of $8.43 million for fiscal year 2025.
- Palomino Laboratories Inc. showed an increase of +6006.2% in Total Assets compared to the prior fiscal year.
- Palomino Laboratories Inc. reported Cash and Equivalents of $8.12 million for fiscal year 2025.
- Palomino Laboratories Inc. showed an increase of +5931.2% in Cash and Equivalents compared to the prior fiscal year.
- Palomino Laboratories Inc. reported Stockholders Equity of $8.10 million for fiscal year 2025.
- Palomino Laboratories Inc. showed an increase of +44335.2% in Stockholders Equity compared to the prior fiscal year.
- Palomino Laboratories Inc. reported Operating Income of -$2.70 million for fiscal year 2025.
- Palomino Laboratories Inc. showed a decrease of -44042.3% in Operating Income compared to the prior fiscal year.
- Palomino Laboratories Inc. reported Shares Outstanding of 18.77 million shares for fiscal year 2025.
- Palomino Laboratories Inc. showed an increase of +317.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: